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Abstract
Solar lentigo, benign lesions which mostly appear on chronically, sun-exposed surfaces, are
associated with ageing. Patients are increasingly requesting a more uniform skin texture,
especially for hands. Treatment options include dermoabrasion, intense pulsed light, cryo-
therapy, peelings, and laser therapy. Topical compounds can be employed, in alternative or
associated with dermatologic procedures. The current study was designed to evaluate solar
lentigo hyperpigmentation, skin architecture and clinician and patient assessments compar-
ing a dermocosmetic lightening product (active) with a moisturizing product (control) accord-
ing to clinical, digital and subjective analyses in 72 lesions over 12-month follow up period.
Statistically significant differences were observed between the lesions treated with the
active compared to the control in terms of papillary brightness (p = 0.03) and contrast (p =
0.03), and in the limitation of dermal-epidermal junction destructuring (p = 0.03) according to
dermal-epidermal junction destructuring score at Reflectance Confocal Microscopy. Lumi-
nance (p = 0.04) and redness (p = 0.03) were improved at color analysis, and physician and
patient evaluations favored the active in efficacy and patient satisfaction investigations. The
dermocosmetic lightening product utilized in the current study proved to be more effective,
according to clinical, digital and subjective analyses in reducing lesion hyperpigmentation,
stabilizing the lesion skin architecture and increasing patient satisfaction compared to the
control in a cohort of 36 subjects, over a 12-month period. Beside demonstrating the efficacy
of this topical lightening product, we propose a “destructuring score”, which improves the
robustness of solar lentigo’s evaluation, and can be used in future studies to standardize the
quantitative comparisons of different treatment options.
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Introduction
Solar lentigo lesions are a widespread aesthetic and social concern, as they are associated with
ageing. Solar lentigo lesions are benign and mostly appear on chronically, sun-exposed sur-
faces (face and scalp, dorsum of the hands, neckline and upper back), and are frequently pres-
ent among the elderly population. Estimates suggest that >90% of Caucasians over 50 years
old are affected [1].
Solar lentigo lesions are small, light to dark brown, flat and are usually smooth. At dermo-
scopy they appear as a faint to dark brown reticular pattern (fingerprinting) or a homogeneous
pattern of pigmentation with sharply demarcated moth-eaten borders [2,3]. The most striking
features of solar lentigo lesions using Reflectance Confocal Microscopy (RCM) are the polycy-
clic papillary contours at the dermal-epidermal junction (DEJ) and cord-like structures corre-
sponding to the elongated rete ridges seen in histopathological analysis [4,5].
Patients are increasingly requesting a more uniform skin texture, especially for the hands.
Treatment options include dermoabrasion, intense pulsed light (IPL), cryotherapy, peelings,
and the current gold standard laser therapy. Topical compounds can be employed, as an alter-
native or associated with dermatologic procedures; the main active ingredients for skin light-
ening are hydroquinone, retinoids, azelaic and salycilic acids [6].
Solar lentigines have previously been assessed by RCM [7,8,9], but to date, investigations of
topical dermocosmetic lightening products in solar lentigines have mostly been assessed with
clinical scoring [10].
The current study was designed to evaluate solar lentigines hyperpigmentation, skin archi-
tecture and clinician and patient assessments comparing a dermocosmetic lightening product
with a moisturizing product according to clinical, digital and subjective analyses in a large pop-
ulation with a long (12-month) application and follow up period.
Materials and methods
Study design
This was an intra-individual, randomized, hand controlled open label study conducted over a
12-month period in Modena, Italy with an allocation ratio of 1:1. Participants were enrolled
into the study between 06 May 2013–26 June 2013. The study was conducted following the
principles of the Declaration of Helsinki and approved by the Ethics Committee of the Univer-
sity of Modena and Reggio Emilia (prot. no. 1428, 20/13). All included participants gave writ-
ten informed consent. The trial was registered (ClinicalTrials.gov NCT03457246), and the full
trial protocol is available (S1 Protocol). As the local Ethics Committee did not require registra-
tion of the trial, registration was completed after patients’ enrolment, according to the editorial
request. The authors confirm that there are no ongoing or related trials for this topical dermo-
cosmetic lightening product.
Fig 1 shows the study design of the trial (Fig 1). Of the 40 patients assessed for eligibility, a
target lesion per hand was chosen (one on the right hand, and one on the left hand). Treatment
was then randomized according to which hand would receive topical treatment. A total of 36
subjects (72 lesions), were entered into final analysis, following the loss to follow-up of 4
patients (8 lesions). There were no changes to methods after trial commencement.
Population
Patients were selected and enrolled by the study co-investigators following dermoscopic diag-
nosis of solar lentigo and according to an inclusion criteria specifying both male and female
subjects 50 years and older, with skin phototype from II to IV according to Fitzpatrick’s
Solar lentigo dermocosmetic lightening product
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classification and who gave written, informed consent to participate in the study. Subjects
were excluded according to their intention to visit a region with a significant increase in sun
exposure conditions compared to their usual place of residence (>7 days), women with child-
bearing potential, and subjects considered unlikely to remain compliant for the study period
according to investigators’ judgement. The inclusion criteria related to solar lentigines were:
the presence of at least 5 lentigines on the surface of each hand, characterized by the same
severity; the target lentigo had to be moderately, markedly or extremely darker than the pig-
ment of the peri-lesion area (4 mm), as assessed by investigators’ initial clinical evaluation.
Subjects were also excluded according to any previous treatment for lentigines (especially laser
Fig 1. CONSORT flow chart of the study design.
https://doi.org/10.1371/journal.pone.0214714.g001
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treatment) within 8 weeks of enrolment, the presence of hyperpigmentation other than lenti-
gines or other hypermelanosis (post-inflammatory hyperpigmentation, such as post-laser or
chemical burning) and any other skin disorders or lesions on the dorsum of the hand. Any
subjects with known hypersensitivity, allergy or intolerance to retinaldehyde or any other
ingredient of the topical compounds were also excluded. Furthermore, diabetic subjects and
subjects with chronic, progressive or systemic infectious diseases, which were considered as
potential influencing factors for the study as judged by the investigator, were not included.
Topical products
A randomization list was established prior to enrolment by the study sponsor and was con-
cealed from the study investigators. At T0, the co-investigators allocated the study products to
each subject according to the chronological order of arrival at the randomization visit, through
a sequentially numbered letter allocation prepared by the study sponsor, without any restric-
tions. Following product assignment, investigators were no longer blinded to allocation. The
tested active product was a topical dermocosmetic lightening product (D-Pigment, labora-
toires Eau Thermale Avène, Pierre-Fabre, Boulogne, France), with a rich texture, containing
phenylethyl resorcinol (0.5%, lightening agent), retinaldehyde (0.05%, a natural retinoid deriv-
ing from vitamin A) and tocopheryl glucoside (0.1%, photo-stable anti-oxidant precursor of
vitamine E) as active ingredients. The reference product (RV2300G) was a moisturizer for
cutaneous use (Hydrance, laboratoires Eau Thermale Avène, Pierre-Fabre, Boulogne, France),
containing thermal water and shea butter.
The administration of the topical products was outlined by the protocol; application once a
day (in the evening after hygiene), of the dermocosmetic lightening product on one hand and
the moisturizer product on the other hand, for a period of 12 months. The products’ applica-
tion was randomized to either hand. Patients were instructed to apply a dosage of each topical
product equivalent to the size of a pea. Patients were given indications to avoid the application
of sunscreens during the study period and any topical products on the day of the visits. The
products were dispensed at each scheduled visit and investigators collected the products
already consumed (empty tubes).
Scheduled visits
Digital standardized photos, color calibrated imaging [11] and Reflectance Confocal Micros-
copy (RCM) acquisitions were performed during each visit; T0 (baseline), T3 (3 months), T6
(6 months), T9 (9 months) and T12 (12 months). Standardized photos were taken at baseline
using a mask to standardize the same area of the hands and enable reproduction of the exact
location of the target lesion during the follow-up (Fig 2).
RCM evaluation
RCM images were acquired by Vivascope 3000 (MAVIG GmbH, Munich, Germany) at T0,
T3, T6, T9 and T12. Vivascope 3000 generates horizontal sections of the skin corresponding to
an area of 850 μm x 850 μm, using a near-infrared laser at 830 nm and operating at a power of
less than 20 mW. For the study, a series of images were acquired from the center of each lesion,
in sequence from the surface up to 150–200 μm in depth, each separated by 5 μm steps, gener-
ated by means of an automatic property software, Vivastack (MAVIG GmbH, Munich, Ger-
many). The features evaluated included those observed at the dermal-epidermal junction
(DEJ).
Intensity of papillary brightness. A descriptive analysis was performed on the full sam-
ple, and frequencies and percentages of the intensity of papillary brightness were calculated at
Solar lentigo dermocosmetic lightening product
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each time-point, according to a numerical qualitative scale ranging from 1 to 3; 1: mild bright-
ness resembling healthy skin; 2: intermediate brightness; 3: intense and sharp brightness of the
papillary rim, due to a hyperpigmentation (melanin) of keratinocytes and melanocytes form-
ing the rim (Fig 3).
Fig 2. Digital standardized photo. Standardized photos were taken at T0 (baseline) with a plastic film placed over the
hands to enable reproduction of the exact location of the target lesion during the follow-up.
https://doi.org/10.1371/journal.pone.0214714.g002
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Papillary contrast. Images were analyzed with a software developed by Pierre Fabre’s
imaging team to enable a semi-automated analysis of papillary contrast in the DEJ, at the level
of 20 μm below the suprapapillary epidermal plateau. Papillary contrast was defined as the dif-
ference in brightness between the cellular ring around the papilla zone and the central dermal
papilla zone, as described by Garrigo Lagarrigue et al. [12]
The dermal-epidermal junction (DEJ) destructuring score. The DEJ was assessed
according to the most prevalent papillae features:
(i) Round papillae: Dark roundish and regular spaces surrounded by a rim of bright hyper-
reflective cells (edged papillae), corresponding to pigmented keratinocytes and
melanocytes.
(ii) Scalloped rings: Dermal papillae surrounded by a rim of small bright cells appearing as
irregular bright rings sharply contrasting with the dark background.
(iii) Enlarged interpapillary spaces: Their presence or absence was evaluated at the DEJ, with
respect to tightly packed papillae visible in solar lentigo and seborrheic keratoses.
(iv) Polycyclic papillary contours: Irregularly shaped dermal papillae, polymorphous and
crowded, with annular and polycyclic bright contours surrounding dark irregular spaces.
Their presence or absence was defined at the DEJ.
In each of the four quadrants of the image acquired (upper right, upper left, lower right and
lower left) (Fig 4), the most prevalent feature was noted. The authors propose a score for “DEJ
destructuring” which includes the features of the lesion RCM image, weighted according to
round papillae = 0; enlarged interpapillary spaces = 1; scalloped rings = 2; polycyclic papillary
contours = 2. If these features are not present, their absence is considered 0. Each quadrant’s
predominant feature is assigned a numeric value and the final score (the addition of each
quadrant’s numerical value) is a value on the scale from 0–8.
Color analysis
The target lesions were visualized by a high-magnification, skin imaging camera (BME; Arti-
gues-pres-Bordeaux, France). The device, with a high-resolution (3 Mpixels), was color-
Fig 3. Intensity of papillary brightness. The intensity of papillary brightness is calculated through a numerical qualitative scale ranging from 1 to 3; 1: mild brightness
resembling healthy skin; 2: intermediate brightness; 3: intense and sharp brightness of the papillary rim, due to a hyperpigmentation (melanin) of keratinocytes and
melanocytes forming the rim.
https://doi.org/10.1371/journal.pone.0214714.g003
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calibrated as described by Vander Haeghen et al. [13] and optimized for color measurement
on a 1 mm2 area [11]. A manual delineation of the target lesion was performed on each image
and the color parameters (CIE-Lab) were calculated. Image processing and color measure-
ments were performed with a home-made software.
As the skin color evolves seasonally, the results were corrected for seasonal variations, (Fig
5). The mean color value of the reference lentigines was used as a color reference at each time
point to correct the seasonal effect.
Physician analysis
Dynamic Physician Global Assessment (PGA) was performed to assess the direct effect of the
topical treatment on the target lesion activity at T3, T6, T9 and T12. Scoring was recorded
according to a comparison with baseline as: completely cleared, very significant clearance, sig-
nificant clearance, moderate clearance, slight clearance and no change [14].
Tolerance for the use of the dermocosmetic lightening product was assessed by the investi-
gator at T3, T6, T9, and T12 using a 4-points scale: 1: very good tolerance and no functional or
physical signs at examination; 2: good tolerance with transitory functional signs and no
Fig 4. Papillae features assessed for the “DEJ destructuring” score. Evaluation of the most prevalent feature in each
of the four quadrants of the image acquired (high left, high right, bottom left, bottom right).
https://doi.org/10.1371/journal.pone.0214714.g004
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physical signs at examination; 3: poor tolerance with persisting functional signs or physical
signs from examination leading to modification of the conditions of administration but no
application discontinuation; 4: very poor tolerance with functional and/or physical signs from
examination leading to application discontinuation.
Patient evaluation
A non-blinded patient efficacy assessment was performed for the global hand at T3 and T12,
and noted in the patient file by the physician according to a 5-points scale: 0: completely
improved, 1: mostly improved, 2: slightly improved, 3: not improved, 4: worsened.
Patient satisfaction was collected with a cosmetic agreement questionnaire, designed for the
current study, with multiple-choice answers, and was administered at T3. Questionnaires were
independently completed, without the intervention of the physician. The frequencies and the
percentages of the evaluated parameters were calculated, comparing the dermocosmetic light-
ening product to the moisturizer product.
Adverse events
Adverse events were defined as any noxious event, related or unrelated to the research or stud-
ied products. Events were graded as: mild, awareness of signs and symptoms, but easily toler-
ated; moderate, uncomfortable enough to cause interference with usual activity; and severe,
incapacity with inability to work or do usual activity.
Data collection and protocol deviations
All clinical data was collected and saved in a computerized database by the study sponsor,
except for RCM data, which was collected and saved in a computerized database at the
Fig 5. Color analysis. Seasonal effect of luminance of reference lentigines throughout the year.
https://doi.org/10.1371/journal.pone.0214714.g005
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Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy. Due to
technical issues with the quality of RCM images at T12, these evaluations were excluded from
final analyses.
Major protocol deviations considered for the study included non-compliance with the
inclusion or non-inclusion criteria, loss to follow-up, no assessment of the primary efficacy cri-
terion and non compliance with products application (considered > 30% of missed applica-
tion between 2 consecutive visits and> 30 days of sun exposure).
Statistical analysis
Due to the lack of available data in literature, sample size calculation had no statistical rationale
but a total of 30 subjects was considered satisfactory for study analyses. Assuming some sub-
jects loss to follow-up over the entire study period of 12 months, a total of 40 subjects were
recruited. Statistical analysis with the SAS software (Copyright 2014, SAS Institute Inc., Cary,
NC, USA) was performed, including an analysis of covariance using a likelihood-based,
mixed-effects model for repeated measures (MMRM) [15], from T0 to T12. Product, site and
sequence were considered fixed factors (well-defined categorical variable), subjects were con-
sidered random factors (random sample of the entire population) and values at baseline were
considered covariates (quantitative variable that can affect the outcome of the study).
Results
Among the 40 recruited subjects, 4 were lost during the follow up period. Follow-up was final-
ized for all 36 included subjects on 09 June 2014. The data of the 36 subjects with a total of 72
lesions were considered according to originally assigned allocation. Among the 36 subjects, 1
subject missed the programmed visit at T6 and 1 missed the visit at T9. Of the 36 subjects, 34
were female (94.4%) and 2 were male (5.6%); the mean age was 61.4 ±8 years old (range from
50 to 79). None of the 34 females presented childbearing potential; 29 of them were in meno-
pause and 5 had a previous history of ovariectomy and/or hysterectomy.
More than half (21–58.3%) of the enrolled subjects were phototype III (sometimes burns
slightly, tans uniformly), 13 (36.1%) phototype II (usually burns slightly, tans slightly) and 2
(5.6%) phototype IV (burns slightly, always tans), (Table 1).
RCM evaluation
A statistically significant difference was observed between the lesions treated with the dermo-
cosmetic lightening product compared to the moisturizing product in terms of papillary
brightness intensity at 3 months (p = 0.03). This improvement was maintained but was not sta-
tistically different from the moisturizing product during the follow-up period T6 and T9 (Fig
6). There was a statistically significant difference also between the groups for papillary contrast
Table 1. Demographic data. Demographic data of the 36 patients enrolled into the study with complete follow-up.
Study population, n 36
Gender, female (%) 34 (94)
Mean age, yrs (range) 61.4 (50–79)
Phototype (Fitzpatrick classification), n (%):
II 13 (36)
III 21 (58)
IV 2 (6)
https://doi.org/10.1371/journal.pone.0214714.t001
Solar lentigo dermocosmetic lightening product
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(p = 0.03), (Fig 7). The global effect of the dermocosmetic lightening product was found to be
statistically significant in limiting the DEJ destructuring (p = 0.03), (Fig 8).
Color analysis
Color analysis revealed a statistically significant improvement in the lentigines luminance
(p = 0.04) and the degree of redness (p = 0.03) for subjects treated with the dermocosmetic
lightening product compared to moisturizing product (Fig 9).
Fig 6. RCM and papillary brightness intensity. Papillary brightness intensity score at Reflectance Confocal
Microscopy (RCM) over the 9 month follow-up period: dermocosmetic lightening product (solid line) and
moisturizing product (dotted line).
https://doi.org/10.1371/journal.pone.0214714.g006
Fig 7. RCM and papillary contrast. Papillary contrast at Reflectance Confocal Microscopy (RCM) over the 9 month
follow up period: dermocosmetic lightening product (solid line) and moisturizing product (dotted line).
https://doi.org/10.1371/journal.pone.0214714.g007
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Physician analysis
The dermocosmetic lightening product was considered by the physician according to the PGA
assessment to have a direct effect on skin improvement. The improvement was statistically
greater than that measured for the moisturizing product at T6, T9 and T12, compared to T0
(p = 0.0036, p<0.001, p = 0.017, respectively), (Fig 10A and 10B).
Tolerance was evaluated for both products as “very good” for all subjects, at each scheduled
visit after the baseline.
Patient evaluation
Patient efficacy assessment revealed an improved overall efficacy for the dermocosmetic light-
ening product compared to the moisturizing product at long term (T12, p<0.001) but there
was no difference observed in the short term (T3, p = 0.175), (Fig 11).
A statistically significant difference between the groups in terms of reported improvement
in patient satisfaction on the target lesion for the depigmentation agent was found. A total of
38 of the 39 patients who responded to the questionnaire, reported being pleased or very
pleased with the product after 3 months of application. Additionally, 87% of patients assessed
the skin as more uniform and 92% agreed that the complexion and pigmentation was reduced.
Other questionnaire results are outlined in Table 2.
Adverse events
There were few adverse events during the study. None were related to the study products and
most were of mild intensity. There were no serious or severe adverse events during the study.
Protocol deviations
There were 4 patients lost to follow up (preprogrammed visits not performed with subsequent
missing evaluation of primary criterion). Furthermore, 4 major protocol deviations were
Fig 8. RCM and DEJ. DEJ destructuring score over the 9 month follow up period: dermocosmetic lightening product
(solid line) and moisturizing product (dotted line).
https://doi.org/10.1371/journal.pone.0214714.g008
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registered: 2 cases of excessive sun exposure (>30 days throughout the year) and 2 missed
doses application (>30%) at final follow-up.
Discussion
Clinical studies designed to evaluate the lightening effect of active ingredients on solar lenti-
gines usually use clinical scoring as the single endpoint [10,16–18]. In order to respond to the
need for a more robust approach in measuring the effectiveness of a lightening topical product,
the present study proposes a unique design including clinical, digital and subjective analyses.
Further, most studies on lentigines are performed over a short period of up to 3 months
[17,19–22], and with a limited number of enrolled subjects, with an average of 10–20 subjects
Fig 9. Color analysis. Color analysis for the lentigines luminance (Fig 9A) and the degree of redness (Fig 9B) for
subjects treated with the dermocosmetic lightening product compared to moisturizing product; dermocosmetic
lightening product (solid line) and moisturizing product (dotted line).
https://doi.org/10.1371/journal.pone.0214714.g009
Solar lentigo dermocosmetic lightening product
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per study [19,23]. The current study design included a longer follow up of 12 months, enabling
the consideration of seasonal impact on lentigines pigmentation on a relatively large popula-
tion cohort of 36 subjects and a total of 72 lentigines.
Fig 10. Physician global assessment. Fig 10A: clinical evaluation according to the dynamic Physician Global
Assessment (PGA) of the 72 target lesions, presented according to the topical product applied. Fig 10B: clinical images
of the 3 categories of improvement observed according to the PGA scale; slight clearance (a: T0, a’: T12), moderate
clearance (b: T0, b’: T12) and significant clearance (c: T0, c’:T12), respectively.
https://doi.org/10.1371/journal.pone.0214714.g010
Solar lentigo dermocosmetic lightening product
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Fig 11. Patient evaluation. Patient efficacy assessment as either slightly improved, mostly improved or not improved.
https://doi.org/10.1371/journal.pone.0214714.g011
Table 2. Patient satisfaction. Patient satisfaction outcomes for all patients after 3 months of the application of the dermocosmetic lightening product.
Questionnaire Patients’ Responses, n (%)
Overall satisfaction: Not pleased 0 (0)
Fairly pleased 1 (2.6)
Pleased 22 (56.4)
Very pleased 16 (41)
Product texture: Unsatisfied 0 (0)
Satisfying 16 (41)
Very satisfying 23 (59)
Skin penetration: Unsatisfied 0 (0)
Satisfying 15 (38.5)
Very satisfying 24 (61.5)
Sensation of the skin after product application: Comfortable: Fresh & clean: Sticky:
No 0 (0) 4 (10.3) 34 (87.2)
Yes, a little 3 (7.7) 9 (23.1) 5 (12.8)
Yes 24 (61.5) 23 (59) 0 (0)
Yes, absolutely 12 (30.8) 3 (7.7) 0 (0)
Skin following product application: Skin more uniform: Complexion and pigmentation reduced: Intensity of the spots attenuated:
No 5 (12.8) 3 (7.7) 1 (2.6)
Yes, a little 13 (33.3) 21 (53.8) 22 (56.4)
Yes 16 (41) 11 (28.2) 13 (33.3)
Yes, absolutely 5 (12.8) 4 (10.3) 3 (7.7)
Comparison to other products previously used: Inferior 0 (0)
Equivalent 14 (53.8)
Better 8 (30.8)
Not applicable� 4 (15.4)
� not applicable: patients without previous product experience.
https://doi.org/10.1371/journal.pone.0214714.t002
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Various options are available for the removal of solar lentigines, such as lasers (CO2,
Q-Switched Nd-YAG, Ruby), intense pulsed light, cryotherapy and topical bleaching actives
[6,23–34]. The advantages of a topical product for solar lentigines’s treatment are numerous.
Dermocosmetics have no associated risks, are non-invasive and do not require a healing
period after treatment, therefore reducing the risk of post-inflammatory hyperpigmentation,
as compared to cryotherapy, IPL and laser treatments. Another important advantage, deriving
from the application of a cream, is the possibility to treat the whole hand (lentigines and peri-
lesion areas) for a more uniform appearance, instead of the ablation of the single lesion
obtained with other treatment options. This can provide a “preventive” action, as it has been
described that there is subclinical alterations observed in the lentigines peri-lesional area [35].
Further, the depigmenting agents employed in this study, including phenylethyl resorcinol
0.5%, retinaldehyde 0.05% and tocopheryl glucoside 0.1%, have been proven to be well toler-
ated into the long term [36–38]. Regular application is therefore safe for the treatment and
maintenance of a chronic aesthetic issue, such as solar lentigines. Additionally, the application
of a topical treatment is a common daily gesture, cheaper than other interventions, and is a
useful preparative/maintenance therapy associated with more invasive procedures.
Color measurement can quantify the visual perception of colors. It has been shown to be a
precise and robust technique for skin lightening efficacy evaluation [8,22,27,39]. Pierre Fabre
imaging team previously showed that precise skin color measurements can be performed
using a high-magnification color-calibrated camera, also used to follow up lentigines [20]. The
present study includes this new technology. The luminance and redness were both found to be
improved in association with the dermocosmetic lightening product throughout the follow-
up. Additionally, these chromametric findings also corresponded well with patients’ satisfac-
tion. Along with the general improvement of luminance and redness associated with the der-
mocosmetic lightening product, patients reported as early at 3 months, an attenuation of the
spots’ intensity.
The visualization of the skin structures and evaluation of pigment modulation throughout
the study follow-up was performed with RCM, an established non-invasive imaging tool
enabling the visualization of skin structures at various depths, with an almost histologic resolu-
tion [40,41]. Its application in studies dedicated to aesthetic improvements is valuable due to
the avoidance of skin biopsy [42]. RCM is increasingly employed in the diagnostic field and
has become an important device to assess the follow-up of treatments for benign lesions [7]. In
the case of solar lentigines, it has been proven to be effective in in situ pigmentation evaluation
[8]. To our knowledge this is the first study that evaluates the lightening efficacy of a topical
treatment through a standardized analysis of RCM images in lentigines.
Changes in papillary brightness and papillary contrast, both assessed with RCM, were also
reflected in the clinical assessment of visible changes in lentigo’s pigmentation. According to
RCM analysis, the employment of the dermocosmetic lightening product highlighted a statisti-
cally significant difference of papillary brightness intensity at T3 compared with the moisturiz-
ing product and accentuates that the main action of improvement is verified within a 3 month
period, with a further limited improvement observed after 6 months. The seasonal effect over
the 9 month period is clearly visible by the moisturizing product (dotted line, Fig 6). From a
clinical point of view, the non-blinded to treatment assignment physician assessment, reported
an improvement in the target lesion treated with the dermocosmetic lightening product, both
at T6 and T9, in comparison to baseline. These results were also well translated into patient’s
satisfaction assessment throughout the study. At the first patient survey (T3), the intensity of
the target lesions were evaluated as attenuated by 97% of the subjects. This was preserved at
the final questionnaire (T12) as the overall efficacy of the dermocosmetic lightening product
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for the whole hand was assessed as significantly improved, compared to the moisturizing
product.
In the current study, the authors propose a quantitative ‘destructuring score’ in order to
measure the disorganization of the DEJ associated with solar lentigines. The disorganization of
the DEJ of lentigo lesions has previously been described with RCM [4,8,9]. Pollefliet et al.
showed the progression of solar lentigines over time with RCM. The introduction of a score
can provide a more robust comparison between treatment options in future studies. The cur-
rent study have shown the quantitative limitation of natural DEJ destructuring of solar lenti-
gines, associated with sun exposure and ageing, with the use of the dermocosmetic lightening
product compared to the moisturizing product. This was demonstrated by a stabilization of
the destructuring score associated with the dermocosmetic lightening product, compared to
the deterioration of the DEJ, with indications of more disorganization, observed in the hand
treated with the moisturizing product. No adverse events occurred during the study.
However, the study has some limitations. There was a potential ascertainment bias as inves-
tigators, data manager and subjects were not blinded to topical product allocation throughout
the follow-up and data analyses periods. Further, due to the sample size, data should be inter-
preted with caution given the imprecision inherent in small sample studies. The inclusion of
more than one lesion could have assisted in obtaining more robust data. Additionally, the
study protocol limited patients’ sun exposure and application of sunscreen. Finally, adverse
events were not collected according to a standardized method but were simply reported in the
case report form according to common events associated with topical products reported in
literature.
The authors hypothesize that with the integration of a sunscreen daily application, results
could be expected to improve, especially in association with DEJ destructuring. Additionally,
future studies could evaluate the benefit of the associated use of dermocosmetics with other
therapeutic approaches and a comparison of other treatment options for lentigo into the long
term. These would be useful for an accurate comparison of efficacy, patient satisfaction and
economic impact to better define treatment cost-effectiveness.
Conclusions
The dermocosmetic lightening product tested in the study proved to be more effective, accord-
ing to clinical, digital and subjective analyses in reducing lesion hyperpigmentation, stabilizing
the lesion skin architecture and increasing patient satisfaction compared to a moisturizing
product in a large patient cohort over a 12 month period. The introduction of a “destructuring
score”, as proposed by the current authors, could improve the robustness of future evaluations
of solar lentigines treatment options, by providing objective quantitative measurement that
correlates with clinical assessments.
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